Page 12 - Prosthetic voice rehabilitation-5th edition

In a long term study, in a patient cohort with a median device life of 21 days, the ActiValve prosthesis had a median device life of 337 days, which means a 16 fold increase (p<0.001; survival curves above).29 In a study in the USA similar median device life was found for ActiValve, making this a very cost-effective solution for patients, who require frequent replacements.30 12 27. Hilgers FJ, Ackerstaff AH, Balm AJ, Van den Brekel MW, Bing Tan I, Persson JO. A new problem- solving indwelling voice prosthesis, eliminating the need for frequent Candida- and under-pressure- related replacements: Provox ActiValve. Acta Otolaryngol 2003; 123:972-979. 28. Timmermans AJ, Harmsen HJ, Bus-Spoor C et al. Biofilm formation on the Provox ActiValve: Composition and ingrowth analyzed by Illumina paired-end RNA sequencing, fluorescence in situ hybridization, and confocal laser scanning microscopy. Head Neck 2015. 29. Soolsma J, van den Brekel MW, Ackerstaff AH, Balm AJ, Tan B, Hilgers FJ. Long-term results of Provox ActiValve, solving the problem of frequent candida- and under-pressure-related voice prosthesis replacements. Laryngoscope 2008; 118:252-257. 30. Graville DJ, Palmer AD, Andersen PE, Cohen JI. Determining the efficacy and cost-effectiveness of the ActiValve: results of a long-term prospective trial. Laryngoscope 2011; 121:769-776.